On March 13, 2026, Barinthus Bio (NASDAQ:BRNS) released its full-year 2025 financial results, highlighting plans for an all-stock merger with diabetes-focused Clywedog Therapeutics. The transaction, expected to close in the second quarter of 2026, would create a combined Nasdaq-listed company named Clywedog Therapeutics Holdings, Inc., with an anticipated cash runway extending into 2027. During 2025, the company shifted its strategic focus toward immunology and inflammation, progressed its Phase 1 AVALON study of VTP-1000 in celiac disease with encouraging safety and pharmacodynamic results from the single ascending dose stage, and reduced research and development expenses to $25.6 million as earlier programs were phased out. Barinthus Bio ended the year with $71.9 million in cash and is preparing for several upcoming milestones, including Phase 1 multiple ascending dose results for VTP-1000 expected in the second half of 2026 and up to four clinical updates within 18 months following completion of the merger.
Earlier, in January 2025, the company announced a restructuring aimed at concentrating resources on immune tolerance therapies such as VTP-1000 while scaling back efforts in infectious disease and oncology, a shift that contributed to lower R&D spending compared with 2024. Throughout 2025, Barinthus Bio also presented positive Phase 2 data for its legacy hepatitis B candidate VTP-300 and completed the single ascending dose stage of the AVALON trial in December. In early 2026, the company revised its merger agreement with Clywedog to introduce greater flexibility in the exchange ratio and minimum cash requirements, reflecting management’s intention to maintain financial strength while building a differentiated pipeline targeting metabolic and autoimmune diseases for both current and prospective institutional investors.
More about Barinthus Biotherapeutics
Barinthus Biotherapeutics focuses on developing therapies in immunology and inflammation designed to promote immune tolerance and potentially deliver curative treatments. The company has recently redirected its strategy toward autoimmune and metabolic conditions, led by its VTP-1000 program for celiac disease, while infectious disease and oncology programs are expected to progress only through partnerships.